WSU to Study Iraq Toxins' Effect
Spokesman-Review
by Bert Caldwell
Research to examine how exposure might damage offspring of soldiers
Washington State University scientists will use a $1.7 million grant to study what multi-generation genetic damage might be done by toxins U.S. troops could encounter in Iraq.
The research using laboratory rats, not humans, will be the first for the military to examine the epigenetic effects of pesticides, herbicides and other compounds, said lead scientist Michael Skinner, director of the university's Center for Reproductive Biology.
Previous studies have looked at the health effects of other substances, notably the Agent Orange used to defoliate jungles in Vietnam, on the soldiers directly exposed, he said, not on their children or grandchildren.
"The science really had not caught up with the trans-generational stuff," said Skinner, one of several WSU pioneers in the field of epigenetic, or multi-generational, inheritance.
Besides herbicides and pesticides – which and in what combinations has not been determined – the study also will look at the effects of explosives residues, he said.
The four-year study will allow researchers to see how any changes in genetic chemistry that develop are passed along through two subsequent generations of rats, he said, noting that only the first two years of research have been funded.
Among the problems that might develop are kidney disease, or changes in the male and female reproductive organs, he said.
If any genetic markers are identified in rats, Skinner said, follow-up research could look at whether they might show up among members of the military as well.
That would be of particular interest to Dave Holmes, interim chief operating officer of the Institute for Systems Medicine, which was awarded the U.S. Department of Defense grant passed through to Skinner.
Holmes' son, Tim Hammond, did two tours in Iraq with the U.S. Marine Corps.
"They sprayed all kinds of stuff on them," Holmes said.
Although the grant money, the first awarded ISM, will fund work in Pullman, he said the organization's supporters hope any subsequent clinical studies will be done in Spokane.
"There's a lot of excitement about making it happen," he said.
"Fighting for Our Veterans-Supporting Our Troops"
Proudly Serving All Branches & All Eras Since 1999
Proton Therapy for Prostate Cancer
Three words have the ability to shake even the bravest men and women: “you have cancer.” But, as proton therapy patients can attest, cancer doesn’t have to change a person’s way of life.
Buck Mays III, of St. Joe, Ark, served nearly 30 years in the Army National Guard and spent three years on active duty during Desert Storm. Now he is a member of the first group of patients to undergo cancer treatment at the ProCure Proton Therapy Center in Oklahoma City. The Oklahoma City center is only the sixth in the U.S. to offer proton therapy, an alternative to X-ray radiation therapy that spares healthy tissue and results in far fewer short-and-long-term treatment side effects.
“I am so pleased I found a treatment that kills the cancer while keeping my health,” said Buck.
Prostate cancer is treated with surgery, standard X-ray radiation therapy, and frequently the placement of radioactive seeds (brachytherapy). In some cases, "watchful waiting" is chosen where the patient is regularly tested and no therapy is given unless the cancer progresses.
Proton therapy offers an excellent treatment option for prostate cancer. The ability of radiation treatment to control prostate cancer depends on the total dose of radiation delivered. Damage to the bladder and rectum, which are in close proximity to the prostate, can limit the dose of radiation that a patient can receive. With protons, a higher dose can be delivered to the tumor site which can result in better tumor control, while largely sparing the bladder and rectum from radiation damage.1 Studies comparing protons to X-ray therapy have reported that protons are at least as effective but have fewer and less severe side effects.2
1.Vargas C, Fryer A, Mahajan C, et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008;70(3):744-51.
2.Slater, J.D.; Rossi, C.J. Jr.; Yonemoto, L.T.; et al. Proton therapy for prostate cancer: The initial Loma Linda University experience. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59 (2), 348-352.
Search Veterans' Voice Site Below
Entire web
